ω-imidazolyl-alkyl derivatives as new preclinical drug candidates for NASH therapy
T. Diesinger, A. Lautwein, V. Buko, E. Belonovskaya, O. Lukivskaya, E. Naruta, S. Kirko, V. Andreev, R. Dvorsky, D. Buckert, B. Sebastian, C. Renz, D. Müller-Enoch, T. Wirth, T. Haehner
The paper tests two new CYP2E1 inhibitors, I-ol and I-an, in a rat model of NASH, finding they reduce pathological markers and show good tolerability.
bioRxiv · Jun 28, 2019 · PreprintPharmacology & Toxicology